TY - JOUR
T1 - Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies
T2 - A systematic review
AU - Nguyen, Austin H.
AU - Bhavsar, Sheila B.
AU - Riley, Erinn M.
AU - Caponetti, Gabriel C.
AU - Agrawal, Devendra K.
PY - 2016
Y1 - 2016
N2 - High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.
AB - High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.
UR - http://www.scopus.com/inward/record.url?scp=85014040836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014040836&partnerID=8YFLogxK
U2 - 10.5114/wo.2016.65600
DO - 10.5114/wo.2016.65600
M3 - Review article
AN - SCOPUS:85014040836
SN - 1428-2526
VL - 20
SP - 425
EP - 429
JO - Wspolczesna Onkologia
JF - Wspolczesna Onkologia
IS - 6
ER -